



KINEXUS

Kinexus Announces the Launch of New Antibody Microarray Service

Kinex™ Microarray Designed to Expedite the Drug Discovery Process

FOR IMMEDIATE RELEASE JANUARY 21, 2006

VANCOUVER, British Columbia – Kinexus Bioinformatics Corporation, a world leader in functional proteomics research, is pleased to announce the recent launch of its first Kinex™ protein microarray service. The Kinex™ platform is the only commercial antibody microarray service available that is capable of tracking the functional states of hundreds of diverse proteins in human and animal cell and tissue specimens. It is as an ideal first step for the discovery of novel biomarkers, protein-protein interactions, and the generation of cell signalling research leads. This proprietary high-throughput technology allows the simultaneous, rapid and quantitative detection of over 600 proteins for both expression and phosphorylation for as low as US \$1.25 per protein.

Over 515 protein kinases catalyze the phosphorylation of more than 500,000 sites in the 30,000 proteins encoded by the human genome, and many of these phosphorylation sites directly control the functions of these proteins. "Given the complex nature of protein kinases and their critical involvement in over 400 diseases, Kinexus has always focused on conducting and supporting research to specifically track these important enzymes and their targets", said Dr. Steven Pelech, President and founder of Kinexus and a professor of Medicine at the University of British Columbia. By utilizing a proprietary technology that allows highly validated antibodies to be uniformly spotted in quadruplicate on plastic slides, Kinexus clients can now quickly and cost-effectively compare drug treated, diseased and normal samples for differences in protein states to discover drug mechanisms of action or to identify novel drug targets.

The Kinex™ Antibody Microarray is the latest addition to a suite of unique and complimentary proteomics services offered by Kinexus. Discoveries made using the Kinex™ microarray can be quickly validated with the Kinetworks™ custom services, which provide highly quantitative and reproducible immunoblotting data on selected proteins of interest. This information can then be correlated with over 200,000 measurements of protein expression and phosphorylation from thousands of other model systems with a subscription to the on-line KiNET™ database. Custom graphic services are also available to provide publication and presentation-ready data images or graphs. Other complimentary services currently in development include *in vivo* services to prepare extracts from a panel of twelve common human tumour cell lines for drug profiling, and reverse microarrays for the detailed characterization of biomarker leads.

Kinexus currently has agreements with over 800 laboratories in life science companies, universities, government institutions, and hospitals in over 30 different countries. To learn more about the Kinex™ Antibody Microarray service or any of the other proteomics services available, please visit <http://www.kinexus.ca>. Kinexus Bioinformatics Corporation is a private, biotechnology company engaged in the research and development of innovative methods to understand the relationships of signalling proteins in cellular communication networks. The application of this knowledge positions Kinexus and its clients in drug development, rational drug design, disease diagnosis and personalized therapies to improve human health.

**For further information, please contact Kinexus Bioinformatics Corporation
toll free at 1-866-KINEXUS or visit our website at www.kinexus.ca**

PRESS RELEASE - 2006 JANUARY 21